See other companies on Welcome to the Jungle
Personalis
Platform personalising cancer testing
- 201-500 employees
- Healthcare
- B2B
- Machine Learning
- Menlo Park, CA
Jump to section
Company mission
To transform the development of next-generation therapies by providing more comprehensive molecular data about each patient’s cancer and immune response.
-13% employee growth in 12 months
Our take
Personalis is developing biopharmaceuticals for cancer immunotherapies, enabling the next generation of precision cancer therapies and diagnostics.
A leader in advanced cancer genomics, Personalis is evolving its understanding of cancer through the 'Personalis NeXT Platform®'. This provides biopharmaceutical customers and clinicians with information on approximately 20,000 human genes and the immune systems all from a single sample.
Through multiple funding rounds including investors such as, Stanford University, Lightspeed Venture Partners, Abingworth, and Mohr Davidow Ventures, Personalis has obtained capital to further grow its products and advance its knowledge in developing the next generation of cancer diagnostics.
Steph
Company Specialist at Welcome to the Jungle
Funding (last 2 of 3 rounds)
Jan 2015
$33m
SERIES C
Oct 2013
$22m
SERIES B
Total funding: $75m
This company has top investors
Leadership
Atul Butte
(Founder)Previously worked at Stanford University, School of Medicine as a Professor of Pediatrics and as a Chief, Division of Systems Medicine in the Department of Pediatrics.